Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first ...
GSK's belantamab mafodotin reduced death risk by 42% in study
GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...
Medpage Today on MSN3d
Pulled Myeloma Drug Improves Survival in Trial
A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...
Oncology Nurse Advisor3d
Could a Belantamab Mafodotin Combo Be a New Standard for Rel/Ref MM?
Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.
GSK drug cut death risk by 42% in multiple myeloma study
GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...
Medscape4d
Eye Toxicities Are a Growing Concern With Certain ADCs
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...
Daily4d
Blenrep combo accepted for priority review in China in relapsed/refractory multiple myeloma: GSK
London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...
Morningstar6d
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination; benefit seen early and maintained through follow-up Data build on ...
Joplin Globe6d
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial evaluating ...
Stockhouse6d
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination; benefit seen early and maintained through follow-up Data build on findings ...